|
|
|
|
|
|
|
EXPERT-LED JOURNAL CLUB DISCUSSIONS |
|
|
|
|
|
| An Association Between Lower Facility Level PSA Screening Rates and Higher Metastatic Prostate Cancer Incidence Rates, Journal Club
|
Zachary Klaassen, MD, MSc, and Chris Wallis, MD, Ph.D.
In this UroToday Journal Club presentation, Christopher Wallis and Zachary Klaassen highlight a JAMA Oncology publication led by Alex Bryant and Brent Rose titled "The Association of PSA Screening Rates with Subsequent Metastatic Prostate Cancer Incidents at US Veterans Health Administration Facilities".
|
|
|
|
|
|
|
|
|
| Trends in Incidence of Metastatic Prostate Cancer in the US
|
| Zachary Klaassen, MD, MSc, and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen discuss the publication entitled "Trends in Incidence of Metastatic Prostate Cancer in the US." Analysis of the emerging trends suggests that the incidence rates of metastatic prostate cancer have increased significantly and coincide temporally with the US Preventive Services Task Force (USPSTF) recommendations against prostate cancer screening across races and age groups. |
|
|
|
|
|
|
|
|
|
|
| Combination Therapy Associated with Significantly Higher Rates of MFS Compared with ADT Alone Among Men with High-Risk Nonmetastatic Prostate Cancer: STAMPEDE Platform Protocol, Journal Club
|
| Zachary Klaassen, MD, MSc, and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen discuss the publication in the Lancet analyzing new data from the STAMPEDE trial of two randomized controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to androgen-deprivation therapy (ADT) in men with high-risk non-metastatic prostate cancer.
|
|
|
|
|
|
| Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club |
| Zachary Klaassen, MD, MSc, and Chris Wallis, MD, Ph.D.
|
| Christopher Wallis and Zachary Klaassen highlight the Journal of Nuclear Medicine article titled "PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study." The authors' findings support the new EAU classification for biochemically recurrent prostate cancer (BCR), that BCR high-risk groups have higher rates of metastatic disease on PSMA PET than the low-risk groups. |
|
|
|
|
|
 |
|
|
|
|
|
